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INTRODUCTION
Acid sphingomyelinase deficiency (ASMD), commonly known 
as Niemann-Pick disease (NPD) types A and B, is a rare, progres-
sive, and often fatal lysosomal storage disorder (LSD). The meta-
bolic defect in ASMD is deficiency of the lysosomal enzyme acid 
sphingomyelinase (ASM) due to mutations in the sphingomyelin 
phosphodiesterase 1 gene (SMPD1).1 ASM catalyzes hydrolysis 
of sphingomyelin to ceramide and phosphocholine, and ASM 
deficiency results in the progressive accumulation of sphingomy-
elin and other lipids within tissues that are rich in reticuloendo-
thelial cells, including the spleen, liver, lung, bone marrow, and 
lymph nodes. With severe disease, neurons may also be affected. 
ASMD has an autosomal recessive pattern of inheritance, and the 
birth prevalence is estimated at 0.4–0.6/100,000.2 Although NPD 
A is more commonly found in individuals of Ashkenazi Jewish 
ancestry, both forms of ASMD are pan ethnic. ASMD was first 
described in 1914 and is distinct from NPD C, which has a dif-
ferent genetic and biochemical basis as well as a distinct clinical 
profile from ASMD.
Currently, only supportive care is available for patients with 
ASMD, although enzyme replacement therapy (ERT) is in 
clinical development for the treatment of the nonneurologic 
manifestations of ASMD.3 Although the most severe infantile 
neurovisceral form of ASMD (NPD A) is uniformly fatal, indi-
viduals with other ASMD phenotypes may benefit from regular 
assessments for multisystem involvement as early as possible. 
However, the diagnosis of ASMD is often delayed by months to 
years because the complex signs and symptoms overlap with other 
disorders, creating a diagnostic dilemma for many practitioners.
OBJECTIVES OF CONSENSUS DIAGNOSIS 
GUIDELINE
The objective of this consensus document is to present an 
educational resource of current practices for the diagnosis of 
ASMD. Although care of ASMD patients is typically provided 
by metabolic disease specialists/medical geneticists, this guide-
line is directed at primary care providers (e.g., pediatricians and 
internist) and specialists (e.g., pulmonologists, hepatologists, 
and hematologists) so that they will be able to recognize these 
patients to provide the appropriate care and referrals.
METHODS AND PROCESS
An international group of experts in the clinical and labora-
tory evaluation, diagnosis, treatment/management, and genetic 
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Background: Acid sphingomyelinase deficiency (ASMD) is a rare, 
progressive, and often fatal lysosomal storage disease. The underlying 
metabolic defect is deficiency of the enzyme acid sphingomyelinase 
that results in progressive accumulation of sphingomyelin in target 
tissues. ASMD manifests as a spectrum of severity ranging from rap-
idly progressive severe neurovisceral disease that is uniformly fatal to 
more slowly progressive chronic neurovisceral and chronic visceral 
forms. Disease management is aimed at symptom control and regular 
assessments for multisystem involvement.
Purpose and methods: An international panel of experts in the 
clinical and laboratory evaluation, diagnosis, treatment/manage-
ment, and genetic aspects of ASMD convened to review the evidence 
base and share personal experience in order to develop a guideline 
for diagnosis of the various ASMD phenotypes.
Conclusions: Although care of ASMD patients is typically provided 
by metabolic disease specialists, the guideline is directed at a wide 
range of providers because it is important for primary care providers 
(e.g., pediatricians and internists) and specialists (e.g., pulmonolo-
gists, hepatologists, and hematologists) to be able to identify ASMD.
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aspects of ASMD convened at a 1-day meeting to review the 
evidence base and develop a guideline for the diagnosis and 
management of ASMD phenotypes. Published materials as 
well as personal experiences were discussed. These recom-
mendations should be considered a consensus based on expert 
opinion because additional levels of evidence were not always 
available in the literature.
SUBTYPES AND NATURAL HISTORY OF ASMD
Although all patients with ASMD share the same basic meta-
bolic defect, a spectrum of clinical presentations and outcomes 
results from differences in disease severity, which contribute to 
the diagnostic challenges. The severity of ASMD ranges from 
a rapidly progressive infantile neurovisceral disease that is 
uniformly fatal in early childhood to more slowly progressive 
chronic neurovisceral and chronic visceral forms. Variability in 
the amount of residual enzyme activity, the extent of neurologi-
cal involvement, and the rate of disease progression contrib-
ute to the phenotypic spectrum, although currently unknown 
modifiers are also likely to play a role. Predictions of phenotype 
cannot be made solely from the ASM activity determined from 
enzyme assays, which are usually performed white blood cells, 
dried blood spots (DBS), or cultured skin fibroblasts. Likely 
modifiers of disease severity are secondary accumulation of 
other lipids such as sphingosine, ceramide, or cholesterol, 
which are highly bioactive and can lead to cellular and other 
abnormalties.4 Modifier genes and/or environmental factors 
may also influence disease severity, although clear evidence for 
the impact of these variables does not currently exist.
The phenotypic variability of ASMD has led to categorization 
of subtypes based on severity and the degree of neurological 
involvement. The clinical features of the ASMD subtypes, with 
highlights of the similarities and differences between them, are 
described in Table 1. Examples of the clinical presentations 
and diagnostic experience for patients with different ASMD 
subtypes are presented in the Appendix (Case Vignettes). The 
clinical features and natural history of the ASMD subtypes have 
recently been reviewed.4 In this document, we propose a uni-
form terminology for ASMD phenotypes so that the spectrum 
of disease can be better described and to differentiate ASMD 
from the eponymous NPD C.
•	 Infantile neurovisceral ASMD: Also known as NPD A, 
this is the most severe form of ASMD. Patients have little 
to no residual ASM activity. Symptom onset occurs in 
early infancy with rapidly progressive systemic manifes-
tations, including hepatosplenomegaly and pulmonary 
involvement, neurodegeneration, hypotonia, and failure 
to thrive.5 Psychomotor development may progress nor-
mally for several months after birth before plateauing 
between 6 and 15 months of age and then regressing. 
Death is typically before 3 years of age and often results 
from respiratory failure following infection.5
•	 Chronic neurovisceral ASMD: Also known as the interme-
diate form, NPD A/B or NPD B variant6,7 is characterized 
by slower progression of neurological symptoms and 
prolonged survival compared to infantile neurovisceral 
ASMD. Ataxia, gross motor delays, and learning disabili-
ties are commonly seen. Progressive multisystem disease 
manifestations are similar to or more severe than those 
observed in chronic visceral ASMD.
•	 Chronic visceral ASMD: Also known as NPD B, it is char-
acterized by a variable age of onset ranging from infancy 
to adulthood and slowly progressive multisystem disease 
manifestations without neurodegeneration.8–11 Patients 
may have a normal life span or die prematurely from dis-
ease complications that include respiratory failure, liver 
failure, and/or hemorrhage.8,12 The most common initial 
presentation is hepatosplenomegaly in early childhood, 
although mild disease may not be diagnosed until adult-
hood. It is not uncommon for the splenic volume to be 
significant (e.g., greater than ten multiples of normal). 
Common clinical features in childhood include delayed 
growth and puberty, fatigue, and bone and joint pain.13 
Other abnormalities include osteopenia and decreased 
platelet and white blood cell counts. Pulmonary function 
may worsen over time, and interstitial lung disease and 
pulmonary infections are common.11,14 A proatherogenic 
lipid profile (mixed dyslipidemia) is seen early in the dis-
ease course and some patients develop coronary artery 
disease.15–17 Development of hepatic fibrosis ranging from 
minimal to cirrhosis is common,18 and progression of liver 
disease contributes to early mortality in some patients.8,19 
Progressive splenomegaly may result from deposition of 
sphingomyelin and progressive portal hypertension.
DIFFERENTIAL DIAGNOSIS
A common clinical presentation for patients with any form 
of ASMD is hepatosplenomegaly. The liver is the primary 
affected organ in the chronic visceral form of ASMD, with 
fibrosis and development of cirrhosis being major morbidities. 
Transaminases are often increased early in the disease course; 
therefore, the first referral for ASMD patients may be to a hepa-
tologist or gastroenterologist. Differential diagnoses include 
malignancy, primary hepatic disease (e.g., fatty liver, autoim-
mune, chronic hepatitis B–related, cryptogenic cirrhosis), and 
other LSDs associated with distinct hepatosplenomegaly such as 
Gaucher disease, NPD C, and lysosomal acid lipase deficiency 
(LALD). With GM1 and GM2 gangliosidosis, Farber disease, 
the mucopolysaccharidoses, and other metabolic diseases (e.g., 
lysinuric protein intolerance, mevalonic aciduria, transaldolase 
deficiency), hepatosplenomegaly is typically absent or milder 
than with ASMD; however, exceptions can be expected. Focal 
liver abnormalities are common in ASMD. Sudden or progres-
sive increases in splenomegaly may result from infection or 
onset of portal hypertension.
Mixed dyslipidemia is also common for patients with ASMD 
and may be detected by routine testing ordered by the primary-
care physician as part of health maintenance. Lipid profiles are 
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typically characterized by increased LDL cholesterol, VLDL 
cholesterol, and triglyceride levels, whereas HDL cholesterol 
levels are substantially decreased.3,15,17 A similar lipid profile 
is seen in LALD, and decreased HDL cholesterol also occurs 
in patients with Gaucher disease, although the decreases in 
ASMD are much more severe.
Although some ASMD patients do not have overt respiratory 
symptoms, most patients have abnormal pulmonary function, 
which shows a restrictive pattern with low diffusing capacity, 
and abnormal lung imaging with evidence of interstitial lung 
disease (ILD).14 Adult patients with ASMD may present with 
lung-only involvement.20 This expands the differential diag-
nosis to include drug and environmental exposures, certain 
infections, autoimmune disorders, chronic respiratory diseases 
such as cystic fibrosis, and infectious etiologies such as tuber-
culosis. Pulmonary disease in ASMD is represented by a range 
of progressive pathophysiological changes that result in lung 
volume restriction and impaired gas exchange, including lipid 
Table 1 Clinical features and natural history of ASMD by phenotype
Infantile neurovisceral  
ASMD (NPD A)
Chronic neurovisceral ASMD 
(intermediate; NPD A/B)
Chronic visceral  
ASMD (NPD B)
Onset, life span, and 
common genotypes
• Onset in early infancy • Onset in childhood • Onset in childhood/adulthood
•  Death by 3 years (mean age, 
27 months)
•  Premature death from liver and respiratory 
disease; age at death ranges from 
childhood to adulthood
•  Survival to adulthood; progressive 
liver and/or respiratory disease may 
lead to premature death in some 
patients
•  Associated with p.R498L, 
p.L304P, and p.P333Sfs*52 
variants
•  Associated with p.Q294K and p.W393G 
variants
•  Associated with p. ΔR610, 
p.P323A, p.P330R, and p.W393G 
variants
Central nervous system •  Short period of normal 
development followed by loss 
of skills
•  Slow progression of mild neurological 
symptoms following a period of normal 
development that can last from 2–7 years
• No neurodegeneration
•  Mild hypotonia, loss of deep 
tendon reflexes; dysphagia
•  Peripheral neuropathy, extrapyramidal 
signs, psychiatric symptoms, learning 
disabilities
• Ataxia beginning in early childhood
Ophthalmologic •  Ocular “cherry red spot” • Ocular “cherry red spot” or macular halo •  Ocular abnormalities indicative 
of neuronal storage seen in 
some patients in the absence of 
neurologic disease
Gastrointestinal •  Hepatosplenomegaly usually 
by 3 months, can become 
massive
• Hepatosplenomegaly
• Cholestatic jaundice • Splenomegaly usually precedes hepatomegaly
• Feeding difficulties • Liver fibrosis seen in most cases
• Vomiting • Portal hypertension
• Abnormal liver function tests
• Diarrhea
Pulmonary • Interstitial lung disease • Interstitial lung disease on imaging
•  Frequent, recurrent respiratory 
tract infections; aspiration 
pneumonia
• Radiographic findings can be very abnormal, with no apparent symptoms
• Restrictive pattern on PFT
Cardiac • Cardiac symptoms not seen • Cardiac valve disease
• Mixed dyslipidemia with low HDL-C
• Early-onset coronary artery disease
Musculoskeletal • No skeletal manifestations • Bone and joint pain
• Reduced bone density and pathologic fractures
• Delayed bone maturation
• Growth restriction in childhood
Hematologic •  No hematologic symptoms or 
mild thrombocytopenia
• Thrombocytopenia with bleeding tendencies
Other •  Poor sleep and irritability • Headache
• Recurrent ear infections
ASMD, acid sphingomyelinase deficiency; NPD, Niemann-Pick disease.
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accumulation in macrophages within the alveolar septa, bron-
chial walls, and pleura.8 An additional factor may be an inflam-
matory component observed in the ASM knockout mouse 
model that drives the recruitment of macrophages to the lung.21
DIAGNOSTIC LABORATORY TESTING
It is the consensus of the advisory panel that when there is 
suspicion of ASMD, an enzyme assay for ASM activity should 
always be performed first, with gene sequencing to follow once 
the biochemical diagnosis has been confirmed. Simultaneous 
determination of glucocerebrosidase activity to distinguish 
ASMD from Gaucher disease is recommended. Gene sequenc-
ing can be diagnostic if two pathogenic mutations are detected; 
however, most genetic variants are not pathogenic. Therefore, 
gene sequencing should not be the first approach to diagnosis 
because it typically takes longer than enzyme activity and may 
delay definitive diagnosis in patients affected with a disorder 
other than ASMD. Demonstration of missing or significantly 
diminished enzyme activity remains the proof of the presence 
of the disease, especially in view of the many unique mutations 
or genetic variants of unknown significance. Results from other 
clinical and laboratory assessments, such as the presence of 
characteristic lipid-laden foam cells present in the liver, spleen, 
airways, and bone marrow, together with low platelet levels and 
mixed dyslipidemia (low HDL cholesterol with high levels of 
LDL cholesterol and triglycerides), although highly suggestive 
of ASMD, are not substitutes for the need to obtain confirma-
tory enzyme test results.
To standardize testing and ensure its diagnostic value, it is 
suggested that laboratory centers of excellence should be estab-
lished based on the minimum number of tests per month, 
ISO 15189 or similar accreditation, and access to physicians 
involved in patient care. At minimum, preferred methodologies 
should be used by all testing laboratories as described here. Of 
note, residual enzyme activity should not be used as a predictor 
of phenotype; instead, positive enzyme testing should be used 
in concert with molecular and clinical assessments.
Best practice for enzyme testing
Tandem mass spectrometry (MS/MS) is considered the 
method of choice for assaying ASM activity rather than fluo-
rometric assays due to enhanced analytical range and more 
accurate assessment of enzyme activity in the lower ranges of 
detection, and rather than radiolabeled native sphingomyelin 
substrate due to the need for licensing for use of radiochemi-
cals. Comparisons with fluorometry have determined that 
there is better differentiation between unaffected and affected 
individuals with MS/MS assays.22 Fluorometric substrates for 
ASMD are known to result in high false-negative rates for indi-
viduals who have the p.Q294K (Q292K nomenclature used 
in reference) mutation, which yields anomalous high enzyme 
activity readings.23 In addition to better substrate specificity 
and no need for radiochemicals, tandem mass spectrometry 
allows for multiplexing of the measurement of enzyme activi-
ties that are included in the differential diagnosis of ASMD, 
thereby expediting diagnosis and reducing cost. Currently, this 
includes Gaucher disease (glucocerebrosidase activity). In con-
trast, fluorometry using DBS for glucocerebrosidase assessment 
yields unreliable results and should not be used. In the future, 
acid lipase (acid lipase deficiency) should be added to the MS/
MS panel as well because the signs and symptoms may mimic 
ASMD and ERT is now available for this disorder.
ASM enzyme activity may be measured using isolated periph-
eral blood leukocytes, fibroblasts, and DBS. Laboratories that 
accept samples from around the world usually require whole 
blood, which permits use of the same sample for second-tier 
testing. DBS that are very stable may be used when it is dif-
ficult to ship liquid blood samples to reference laboratories.24 
However, limitations to DBS testing include the potential 
effects of anemia and recent transfusions on results. Therefore, 
it is important for transfusions to be stated on the request 
form, including the time elapsed since the last transfusion and 
transfusion type, because plasma transfusion may have more 
of an impact on enzyme tests than erythrocyte transfusions. 
Cultured skin fibroblasts may be preferred for confirmation of 
enzyme activity in equivocal cases. As noted, because ASMD 
and Gaucher disease have several clinical manifestations in 
common, simultaneous enzyme testing for ASM and glucocer-
ebrosidase should be obtained either as a multiplex test using 
tandem MS analysis or in parallel with singleplex testing.
Gene sequencing
The ASM gene (SMPD1) has been cloned and mapped to chro-
mosome 11p15.1–15.4, and more than 180 mutations have 
been described.4,25 There are currently two numbering systems 
for SMPD1 mutations as a result of two reference sequences 
(GenBank Accession Numbers NM_000543.4 and M81780.1) 
that differ by length polymorphism within the signal peptide 
region. References to mutations should include the appropriate 
reference sequence for clarity; in this article, the NM_000543.4 
sequence was used. Gene sequencing is recommended after 
confirmation of the diagnosis by demonstration of reduced 
ASM activity.
There is a great deal of heterogeneity among SMPD1 muta-
tions, and most mutations are “private,” occurring in only one 
or a few families. However, predictions regarding genotype/
phenotype correlations are possible in some cases for which 
“common” mutations have been found. Frameshift mutations 
due to splicing, small and large insertions and deletions, and 
splicing defects typically result in little or no residual ASM 
activity and are more likely to contribute to severe ASMD. 
Missense and certain other lesions (such as in-frame codon 
deletions) that retain significant residual activity (e.g., >5% of 
wild-type ASM activity depending on the cell and assay system) 
are more likely to result in chronic ASMD. Inheritance is auto-
somal recessive; therefore, the presence of two loss-of-function 
alleles is required to develop ASMD. Phenotype will depend on 
the combination of these alleles.
As noted, in some cases “common” SMPD1 mutations have 
been found in multiple unrelated families. These common 
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mutations provide the most reliable genotype/phenotype cor-
relations. For example, three mutations account for more 
than 90% of infantile neurovisceral ASMD in the Ashkenazi 
Jewish population: p.R498L, p.L304P, and p.P333Sfs.26 The 
most common mutation in patients with the chronic visceral 
form of disease is p.∆R610,27 which is found in 15–20% of all 
North American and Western European patients and is also 
prevalent in patients from North Africa. p.∆R610 is associ-
ated with a higher amount of residual enzyme activity and is 
considered neuroprotective when either homoallelic or het-
eroallelic. A 10-year longitudinal study of 29 patients with the 
chronic visceral form of ASMD showed that attenuated disease 
is associated with homozygosity for mutations such as p.∆R610, 
p.P325A, and p.P332R.10 Common mutations detected in the 
chronic neurovisceral form include p.Q294K6,7 and p.W393G,28 
although the p.W393G mutation is also observed in patients 
with chronic visceral ASMD. There is ongoing research regard-
ing identification and characterization of novel SMPD1 muta-
tions and their phenotypic correlations,25,29 which are likely 
to be improved by development of better computer modeling 
based on ASM structure.
Biomarkers for ASMD
Biomarker assays may be useful for disease monitoring once the 
diagnosis of ASMD is made. However, this is an area of ongo-
ing research, and the finding of increased levels of one or more 
markers is never sufficient to diagnose ASMD, although they 
may be helpful for assessing disease severity. The role of ASMD 
biomarkers may become of greater importance to monitor 
treatment responses as ERT becomes available. The following is 
a brief summary of several biomarkers that have been studied 
regarding their utility as indicators for ASMD.
Plasma chitotriosidase, which is a biomarker of macrophage 
activation, is markedly increase in several LSDs, including 
Gaucher disease30 and chronic ASMD.31 In Gaucher disease, it 
has been proven to be useful for monitoring disease severity 
and effectiveness of ERT.32 Although levels observed in ASMD 
are not as high as those measured in patients with Gaucher dis-
ease, chitotriosidase may serve as a useful biomarker for chronic 
ASMD.33,34 However, up to 6% of individuals have a recessively 
inherited deficiency in chitotriosidase,35 and polymorphisms 
in the chitotriosidase gene that compromise assay results36 
can result in incorrect interpretations of chitotriosidase levels 
measured in plasma. Plasma CCL18 levels are also increased in 
Gaucher disease,37 where it can serve as a surrogate marker for 
disease activity, and in patients with ASMD.34 This marker is 
of particular use when patients have chitotriosidase deficiency.
Plasma lysosphingolipids have been shown to be biomark-
ers of sphingolipidosis in several LSDs. For example, glucosyl-
sphingosine is a specific and sensitive biomarker for Gaucher 
disease and is not increased in other LSDs.38 Lysosphingomyelin 
is increased in DBS and plasma from patients with chronic 
ASMD, suggesting that it may have use as a biomarker; how-
ever, additional studies are needed.39
As noted, dyslipidemia is a common feature of patients with 
ASMD, even at a very early age.3,15,17 Oxysterols are oxygenated 
derivatives of cholesterol that are typically rapidly removed 
from the body during normal cholesterol metabolism but that 
have been shown to be increased in NPD C, chronic ASMD, 
and LALD and may correlate with hepatic disease in patients 
with NPD C.40
DIAGNOSTIC ALGORITHM
Based on the common presenting and associated symptoms of 
ASMD, differential diagnoses, and approaches to diagnostic 
testing described in the previous sections, an algorithm for 
the diagnosis of the infantile neurovisceral form of ASMD 
and the chronic neurovisceral and visceral forms of ASMD 
presenting in childhood is presented in Figure 1. An algo-
rithm for diagnosis of ASMD presenting after childhood is 
shown in Figure 2.
Following biochemical and molecular analyses to confirm the 
diagnosis of ASMD, predictions of phenotypic outcomes will 
permit more appropriate patient care and family counseling. 
Physicians will rely on clinical assessments to predict the phe-
notype and clinical course for pediatric patients when SMPD1 
mutations of unknown pathogenicity are identified.
CONCLUSIONS
Patients with ASMD present with a large phenotypic spectrum 
of nonspecific disease manifestations that can lead to consid-
erable diagnostic delay and missed cases. Early diagnosis of 
ASMD is a priority for appropriate management.
APPENDIx: CASE VIGNETTES
The following are fictitious case vignettes based on real-life 
cases and are meant to describe the symptoms that may help 
differentiate between the different forms of ASMD as well as 
highlight the difficulty in establishing a proper clinical diagno-
sis based solely on a patient’s genotype.
Case 1: Infantile neurovisceral ASMD
A male infant with Eastern European Jewish ancestry presented 
at 3 months of age with hepatosplenomegaly. At 4 months of 
age, notable signs and symptoms included elevated liver trans-
aminases, gastroesophageal reflux, and failure to thrive. In 
addition, at 4 months of age, the patient was hospitalized for 
failure to thrive. Hypotonia with poor head control was noted. 
Enzyme assay for ASM activity was performed at 5 months of 
age and the diagnosis of ASMD was made. Genotyping showed 
a common mutation associated with infantile neurovisceral 
ASMD in patients of Eastern European Jewish ancestry as well 
as a novel frameshift mutation. At 10 months of age, the patient 
was unable to sit independently or hold a bottle. The patient 
had progressive failure to thrive, liver dysfunction, and neuro-
logic deterioration. He died at 2 years of age.
Comment: This is the classic presentation and course for 
infantile neurovisceral ASMD. The severity of the symptoms 
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Figure 1 Diagnostic algorithm for acid sphingomyelinase deficiency presenting in infancy and childhood.







One or more features
suggestive of ASMD:



















Known genotype/phenotype correlations (see reference 25), e.g.:
Unknown genotype/phenotype correlations:




Abbreviations:  ASM = acid sphingomyelinase; ASMD = acid sphingomyelinase deficiency; CHF = congestive heart
failure; HDL-C = high density lipoprotein cholesterol;  LSD = lysosomal storage disorder; MS/MS = tandem mass
spectrometry; SMPD1 = ASM gene 
Splenomegaly
± Hepatomegaly
















One or More Features
suggestive of ASMD:
• Low HDL-C













Abbreviations:  ASM = acid sphingomyelinase; ASMD = acid sphingomyelinase deficiency; CHF = congestive heart
failure; HDL-C = high density lipoprotein cholesterol;  LSD = lysosomal storage disorder; MS/MS = tandem mass
spectrometry; SMPD1 = ASM gene 
 Volume 19  |  Number 9  |  September 2017  |  Genetics in meDicine972
Diagnostic guideline for acid sphingomyelinase deficiency  |  McGOVERN et al Special article
at a very young age together with the relevant ancestry should 
prompt early medical attention and diagnosis.
Case 2: Chronic neurovisceral ASMD
A male child presented with marked abdominal distension, 
chronic diarrhea, and failure to thrive at 6 months of age and 
was referred to a cystic fibrosis specialist. Other signs and 
symptoms of note included severe hepatosplenomegaly and 
hypotrophic muscles. Suspicion of an LSD resulted in refer-
ral to a metabolic specialist, who diagnosed ASMD with an 
enzyme assay. The patient was able to sit without support at 
10 months of age. Laboratory findings included dyslipidemia, 
elevated liver transaminases, thrombocytopenia, and leukope-
nia. Lung involvement included interstitial pneumopathy with 
ground-glass aspect. Genotyping revealed one missense allele 
associated with infantile neurovisceral ASMD or with chronic 
neurovisceral ASMD and one nonsense allele associated with 
infantile neurovisceral ASMD. By 6 years of age, the patient also 
presented with developmental delay and recurrent respiratory 
infections.
Comment: Although some of the presenting features of this 
patient are similar to those of patients with infantile neuro-
visceral ASMD, the child’s developmental milestones did not 
regress as in patients with infantile neurovisceral ASMD. The 
diagnosis at 9 months of age accompanied by a genotype that is 
insufficient to distinguish between infantile neurovisceral and 
chronic neurovisceral disease should make the monitoring of 
clinical signs important for the prediction of the clinical course.
Case 3: Pediatric-onset chronic visceral ASMD
A female child had normal growth and development for the 
first 2 years of life but was then noted to have splenomegaly 
at a routine pediatric visit. The child underwent a diagnostic 
workup for pediatric causes of splenomegaly including CBC, 
viral studies, and liver function tests that were all normal. The 
patient was eventually diagnosed with ASMD at age 6 when 
she developed severe nosebleeds and underwent a hemato-
logic evaluation for thrombocytopenia, at which time she was 
noted to have hepatosplenomegaly and the possibility of a stor-
age disease was added to the differential diagnosis. Genotyping 
revealed two missense mutations. The patient is now 10 years 
old and at the age-appropriate grade level in school, but she has 
not achieved appropriate height and suffers from fatigue. She 
has persistently increased transaminases and dyslipidemia with 
decreased HDL levels and increased triglycerides. Chest X-ray 
showed increased interstitial markings.
Comment: The patient presented with organomegaly, which 
is a common presenting sign in ASMD. The delay in diagno-
sis of 4 years is very common with patients with chronic vis-
ceral ASMD because they frequently have a lengthy diagnostic 
journey.
Case 4: Adult-onset chronic visceral ASMD
A middle-aged male patient was diagnosed with hepatospleno-
megaly following an ultrasound evaluation for abdominal pain. 
A bone marrow biopsy showed Niemann-Pick cells. ASM 
activity was within the affected range, and molecular sequenc-
ing of the SMPD1 gene revealed compound heterozygosity for 
ΔR610 and a mutation associated with infantile neurovisceral 
ASMD. Hepatosplenomegaly was present on abdominal MRI, 
as was an incidental finding of a small adrenal mass thought 
to be consistent with sphingomyelin deposition. Prior to the 
diagnosis, the patient considered himself to be in good health, 
although he had occasional shortness of breath with activity 
and was being treated for hypercholesterolemia. After ASMD 
was confirmed, chest X-ray and chest CT revealed interstitial 
lung disease predominantly within the lung bases. Pulmonary 
function testing revealed a restrictive pattern with low diffusing 
capacity and HDL cholesterol was low; platelets and liver func-
tion test results were within the normal range.
Comment: This patient had hepatosplenomegaly, an abnor-
mal lipid profile with low HDL, and lung findings that were 
consistent with chronic visceral ASMD, although he was not 
diagnosed until much later in life. This case demonstrates the 
milder end of the phenotypic spectrum of ASMD and the fea-
tures (organomegaly, respiratory issues, and mixed lipidemia) 
that are indicative of ASMD onset after childhood.
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